| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | High affinity immunoglobulin gamma Fc receptor IB, IgG Fc receptor IB, Fc-gamma RIB, FcRIB, hFcgammaRIB, FCGR1B, IGFRB |
| WB Predicted band size | 32.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FCGR1B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 248-276 amino acids from the C-terminal region of human FCGR1B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **FCGR1B抗体** 的模拟参考文献示例，基于研究领域常见方向整理：
---
1. **文献名称**: *"Structural insights into the human FCGR1B-IgG complex by cryo-EM"*
**作者**: Müller, R., et al.
**摘要**: 本研究通过冷冻电镜解析了FCGR1B与IgG抗体的复合物结构，揭示了FCGR1B胞外域的高亲和力结合位点，为设计靶向FCGR1B的抗体药物提供了结构基础。
2. **文献名称**: *"FCGR1B polymorphisms modulate antibody-dependent phagocytosis in autoimmune diseases"*
**作者**: Tanaka, Y., et al.
**摘要**: 通过分析系统性红斑狼疮(SLE)患者队列，发现FCGR1B基因多态性影响其与IgG抗体的结合能力，导致单核细胞介导的吞噬功能异常，可能与疾病进展相关。
3. **文献名称**: *"A novel anti-FCGR1B monoclonal antibody suppresses inflammatory responses in sepsis models"*
**作者**: Chen, L., et al.
**摘要**: 开发了一种靶向FCGR1B的单克隆抗体，在脓毒症小鼠模型中证实其可通过阻断Fcγ受体信号通路，显著降低促炎细胞因子释放和组织损伤。
4. **文献名称**: *"FCGR1B expression on macrophages as a biomarker for rheumatoid arthritis activity"*
**作者**: Schmidt, E., et al.
**摘要**: 研究发现类风湿关节炎(RA)患者滑膜巨噬细胞中FCGR1B表达上调，其抗体结合能力与疾病活动度正相关，提示FCGR1B可作为治疗监测的生物标志物。
---
**注**：以上文献为模拟内容，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词：FCGR1B antibody, FCGR1B function, FCGR1B disease)。
**Background of FCGR1B Antibodies**
FCGR1B (Fc gamma receptor Ib), encoded by the *FCGR1B* gene, belongs to the Fcγ receptor family involved in immune responses by binding IgG antibodies. These receptors link humoral and cellular immunity, mediating processes like phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and cytokine release. FCGR1B, a low-affinity receptor, is primarily expressed on myeloid cells, including monocytes, macrophages, and neutrophils. It shares structural homology with other Fcγ receptors but has unique signaling properties due to its cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can dampen immune activation.
Antibodies targeting FCGR1B are tools for studying its role in immune regulation and disease. Dysregulation of FCGR1B is implicated in autoimmune disorders (e.g., lupus), infectious diseases, and cancer, where altered IgG-mediated responses contribute to pathology. FCGR1B-specific antibodies help elucidate its interactions with immune complexes, therapeutic monoclonal antibodies, or pathogens. Additionally, therapeutic anti-FCGR1B antibodies are explored to modulate immune responses—either enhancing effector functions in cancer immunotherapy or suppressing hyperactivity in autoimmune conditions. Challenges include ensuring specificity to avoid cross-reactivity with other Fcγ receptors and optimizing functional outcomes. Research continues to define FCGR1B's precise mechanisms and therapeutic potential in precision medicine.
×
